Healthcare Industry News: Aegerion Pharmaceuticals
News Release - January 13, 2014
Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as DirectorPLYMOUTH, Mich.--(Healthcare Sales & Marketing Network)--Esperion Therapeutics, Inc. (ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
Dr. Gotto currently serves as Co-Chairman of the Board of Overseers of the Joan and Sanford I. Weill Medical College of Cornell University and Vice President of Cornell University. From January 1997 to December 2011, Dr. Gotto served as the Stephen and Suzanne Weiss Dean of the Joan and Sanford I. Weill Medical College of Cornell University and Provost for Medical Affairs of Cornell University. Previously, Dr. Gotto served as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research and Chairman and Professor of the Department of Medicine at Baylor College of Medicine and Methodist Hospital. Dr. Gotto currently serves as a member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the American Academy of Arts and Sciences. Dr. Gotto is also a past president of the International Atherosclerosis Society and a past president of the American Heart Association. Dr. Gotto holds a B.A. degree from Vanderbilt University, a D.Phil. degree in Biochemistry from Oxford University in England, where he was a Rhodes Scholar, and an M.D. degree from Vanderbilt University School of Medicine. He completed his residency training at Massachusetts General Hospital in Boston, Massachusetts. Dr. Gotto is also a member of the Board of Directors of Aegerion Pharmaceuticals, Inc.
Tim Mayleben, president and chief executive office of the Company, said, “We are very pleased to welcome Dr. Gotto to the Esperion Board of Directors. He has extensive experience in atherosclerosis and lipid regulation and prior experience working with us at the original Esperion. We welcome the strategic contributions Dr. Gotto will provide as a board member and look forward to working with him.”
"Throughout my professional career, I have been a supporter of and participant in lipoprotein and atherosclerosis research. Thus, I am very pleased to be joining the Esperion Board of Directors," said Dr. Gotto. “I believe Esperion is well-positioned to make important contributions in the basic and clinical development of novel products for lowering LDL-cholesterol. This would be especially important for statin-intolerant patients. I look forward to contributing to the company’s continued success."
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule therapy designed to lower levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. ETC-1002 is targeted for statin intolerant patients with elevated levels of LDL-C. Esperion has completed seven clinical studies to date, including four Phase 2a studies, and has initiated a robust Phase 2b clinical program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including, without limitation, statements regarding the development and therapeutic potential of ETC-1002. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, the risk that unanticipated developments could interfere with the development (and commercialization) of ETC-1002, as well as other risks detailed in Esperion's filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2013. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Source: Esperion Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.